BioCentury
ARTICLE | Top Story

CeNeS ends opiate deal with BGP

October 30, 2001 8:00 AM UTC

CeNeS (LSE:CEN) said it terminated a 2000 development and licensing deal with Bioglan (LSE:BGP) to develop a sublingual opiate spray product to treat breakthrough cancer pain and pain following surger...